Phase III Lasmiditan Data Strengthens Lilly's Dual Migraine Strategy
Lilly will submit lasmiditan for FDA approval after a second positive Phase III study, giving the company a product to stop migraine when its galcanezumab isn't able to prevent the headaches.
You may also be interested in...
CGRP inhibitors were a hot topic during third quarter earnings calls, with Amgen and Teva talking about reimbursement progress, while Lilly marked progress for its add-on treatment, Allergan calmed fears about Botox's migraine sales, and Alder said its intravenous drug is on track.
Questions loom as to whether Allergan's pair of CGRP antagonists will face the liver toxicity issues that previously plagued oral CGRP drugs. The firm is counting on the migraine therapies to help offset revenues lost to generics.
J.P. Morgan Notebook Day 3: Lilly's CGRP Prospects, Juno On Track, Color From Alnylam's Greene, Shire's New CMO
Daily round-up of news and notes from the 2018 J.P. Morgan Healthcare Conference in San Francisco: Lilly CEO on CGRP reimbursement jitters, Alnylam president on Sanofi deal terms, Juno stakes BCMA myeloma claim, Shire's new CMO.